Target intelligence / Profile preview

Immunoglobulin heavy constant mu (IGHM)

Target
IGHM
Molecular classification
Other (Immunoglobulin, antibody constant region), Receptor (when part of the B cell receptor complex)
01

Overview

Immunoglobulin heavy constant mu is the constant region of the heavy chain defining the **IgM isotype**, one of the main classes of antibody molecules produced by B lymphocytes[1][2][3][5]. It forms part of both membrane-bound and secreted immunoglobulin M. Secreted IgM is the first antibody produced during an immune response, typically as a pentamer, enabling efficient activation of the classical complement pathway and efficient antigen neutralization. Membrane IgM, together with IgD, constitutes the B cell receptor complex on naive B cells, crucial for B cell activation and selection. IGHM deficiency or mutation leads to severe immunodeficiency, manifesting in increased vulnerability to infections. High serum IgM or aberrant IGHM expression can also signal B cell dysfunction, autoimmunity, or lymphoproliferative disorders[1][5].

Other names
Ig mu chain C regionIg mu chain C region BOTIg mu chain C region GALIg mu chain C region OUAGM1MUVHconstant region of heavy chain of IgMimmunoglobulin mu chain
02

Mechanism of action

Not therapeutic antibody target; drugs listed (like zinc) are not specific modulators of IGHM but may interact with immune components[2]; Monoclonal antibodies targeting the IgM isotype/IGHM-expressing cells (used sporadically in research or diagnostics, not as direct therapeutics)

03

Biological functions

Antigen recognition/bindingHumoral immune responseActivation of B cellsIsotype switching in B lymphocytesComplement activationOpsonization and pathogen eliminationMucosal immunity
04

Disease associations

Immunodeficiency (e.g., Agammaglobulinemia 1)Infection (key role in defense against pathogens)Autoimmune disease (role in clearance of autoantigens)Cancer (relevance in B cell malignancies)
05

Safety considerations

Off-target effects of depleting or blocking IgM (impaired humoral immunity, susceptibility to infection)Immune complex disease risk if broadly targeting IgM
06

Interacting drugs

Zinc (approved, investigational; target interaction recognized, but not as a therapeutic antibody directly)[2]

1 more in the full profile.

07

Biomarkers

Serum IgM (for diagnosis of immune status and some immunodeficiencies)IGHM gene mutation (for genetic diagnostics in certain immunodeficiencies)

Beyond the preview

Go deeper on Immunoglobulin heavy constant mu (IGHM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin heavy constant mu (IGHM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call